Artelo Biosciences logo
Artelo Biosciences ARTL
$ 1.35 8.87%

Annual report 2025
added 02-24-2026

report update icon

Artelo Biosciences Cash Flow 2011-2026 | ARTL

Annual Cash Flow Artelo Biosciences

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-8.52 M -8.35 M -8.21 M -8.01 M -2.67 M -4.35 M -2.79 M -1.61 M -217 K - - - - - -

Depreciation & Amortization

- - - - - 500 510 290 - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Artelo Biosciences

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -1.6 M - - - -2.94 M - - - -2.19 M - -5.72 M -4.02 M -2.05 M -2.67 M -4.86 M -3.34 M -1.93 M -1.87 M -3.47 M -2.45 M -1.32 M -1.05 M -1.73 M -1.14 M -1.05 M -401 K -1.1 M -637 K -401 K -170 K -58.9 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- - - - - - - - - - - - - - - - - - 62 60 372 124 124 124 383 243 124 70 249 73 70 72 - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

- - - - - - - - - - - - - - - - - - - - - - - - 639 K 639 K 639 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Artelo Biosciences, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
argenx SE argenx SE
ARGX
$ 834.06 0.94 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 234.24 -0.3 % $ 5 B danmarkDanmark
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 27.99 4.17 % $ 1.59 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.81 1.31 % $ 4.42 M chinaChina
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.33 0.79 % $ 8.01 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.66 1.42 % $ 393 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 167.61 -4.09 % $ 8.34 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biogen Biogen
BIIB
$ 194.87 -0.75 % $ 28.5 B usaUSA
BioVie BioVie
BIVI
$ 1.25 0.4 % $ 1.85 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 63.02 0.15 % $ 12 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.88 0.86 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.72 2.08 % $ 4.55 B usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA